- NCIt
- C7711
Loading cancer entity…
Loading cancer entity…
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03211416 | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | completed | Phase 1 / Phase 2 | 37 | Roswell Park Cancer InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02234986 | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | completed | Phase 2 | 35 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT02695628 | [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer | completed | Phase 2 | 5 | Stanford UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01624285 | Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | completed | Phase 2 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT02024087 | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 21 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Sep 26, 2022 | clinicaltrials |
| NCT01900002 | Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT01835223 | Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT02409524 | An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects | completed | Phase 2 | 15 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT01395030 | PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection | completed | Phase 2 | 64 | Queen's Medical CenterOTHER | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00101036 | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2018 | clinicaltrials |
| NCT00321594 | Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 2 | Nov 6, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02447679 | Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence | completed | Phase 2 | 40 | Chang Gung Memorial HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01777594 | Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma(G-202-003) | completed | Phase 2 | 25 | GenSpera, Inc.INDUSTRY | 1 | Aug 23, 2016 | clinicaltrials |
| NCT01425879 | MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01488487 | Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 7, 2016 | clinicaltrials |
| NCT00055692 | Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00365391 | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2015 | clinicaltrials |
| NCT00107536 | Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00006016 | Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00083226 | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00604721 | Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00639509 | IMC-A12 in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00052364 | Oxaliplatin in Treating Patients With Liver Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00238394 | Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00033462 | Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00077441 | Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00071994 | Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 5, 2026source: clinicaltrials